The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Dipentum 500mg Tablets



Atnahs Pharma Netherlands B.V.PA22657/001/002

Main Information

Trade NameDipentum 500mg Tablets
Active SubstancesOlsalazine sodium
Dosage FormTablet
Licence HolderAtnahs Pharma Netherlands B.V.
Licence NumberPA22657/001/002

Group Information

ATC CodeA07EC Aminosalicylic acid and similar agents
A07EC03 olsalazine

Status

License statusAuthorised
Licence Issued18/05/1995
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back